Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 544-553

  Zhou, Xikun ^a   Li, Jing ^b   Wang, Zhen ^a   Chen, Zhongwen ^a   Qiu, Ji ^a   Zhang, Yinbing ^a   Wang, Wei ^a   Ma, Yu ^a   Huang, Nongyu ^a   Cui, Kaijun ^a   Li, Jiong ^a   Wei, Yu quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; COCULTURE; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROTEIN ENGINEERING; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSFECTION; TUMOR BURDEN;

EID: 84877024985     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13168     Document Type: Article

References (49)

1. Sridhar SS, Seymour L, and Shepherd FA (2003). Inhibitors of epidermalgrowth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4, 397-406.
2. Schmidt M, Reiser P, Hills D, Gullick WJ, and Wels W (1998). Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Int J Cancer 75, 878-884.
3. Herbst RS and Shin DM (2002). Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593-1611.
4. Mendelsohn J (2001). The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8, 3-9.
5. Fish-Steagall A, Searcy P, and Sipples R (2006). Clinical experience with anti-- EGFR therapy. Semin Oncol Nurs 22, 10-19.
6. Karamouzis MV, Grandis JR, and Argiris A (2007). Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298, 70-82.
7. Bush T, Freeman D, Ogbagabriel S, Belmontes B, Kozlosky C, Baher A, Johnson C, Van G, Cerretti D, and Radinsky R (2005). Activity of panitumumab alone and in combination with chemotherapy against mutant epidermal growth factor receptor (EGFr)-expressing non-small cell lung carcinoma (NSCLC) cell lines and xenografts. Clin Cancer Res 11, 9047s.
8. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, and Radinsky R (2009). Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 8, 1536-1546.
9. Rossi A, Maione P, and Gridelli C (2006). Cetuximab in advanced non-small cell lung cancer. Crit Rev Oncol Hematol 59, 139-149.
10. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, et al. (2008). Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol 3, 1286-1292.
11. Thurber GM, Schmidt MM, and Wittrup KD (2008). Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60, 1421-1434.
12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-967.
13. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313, 1485-1492.
14. Morgan RA, Dudley ME, and Rosenberg SA (2010). Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 16, 336-341.
15. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, and Dudley ME (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8, 299-308.
16. Yee C (2010). Adoptive therapy using antigen-specific T-cell clones. Cancer J 16, 367-373.
17. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
18. Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, and Debets R (2010). T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther 10, 547-562.
19. Gross G, Waks T, and Eshhar Z (1989). Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86, 10024-10028.
20. Gross G, Gorochov G, Waks T, and Eshhar Z (1989). Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 21, 127-130.
21. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271.
22. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102.
23. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14, 1264-1270.
24. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, and Oosterwijk E (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24, e20-e22.
25. Zhou X, Qiu J, Wang Z, Huang N, Li X, Li Q, Zhang Y, Zhao C, Luo C, Zhang N, et al. (2012). In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol 138, 1081-1090.
26. Zhou X, Li X, Gou M, Qiu J, Li J, Yu C, Zhang Y, Zhang N, Teng X, Chen Z, et al. (2011). Antitumoral efficacy by systemic delivery of heparin conjugated polyethylenimine-plasmid interleukin-15 complexes in murine models of lung metastasis. Cancer Sci 102, 1403-1409.
27. Khong HT and Restifo NP (2002). Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3, 999-1005.
28. Kim JH, Majumder N, Lin H, Chen J, Falo LD Jr, and You Z (2005). Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 11, 941-949.
29. Tian S, Liu Z, Donahue C, Falo LD Jr, and You Z (2012). Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccineinduced prophylactic and therapeutic antitumor immunity. Mol Ther 20, 432-442.
30. Schrama D, Reisfeld RA, and Becker JC (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5, 147-159.
31. Brekke OH and Sandlie I (2003). Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2, 52-62.
32. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, and Morgan RA (2011). Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19, 751-759.
33. Porter DL, Levine BL, Kalos M, Bagg A, and June CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725-733.
34. Yarden Y (2001). The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(suppl 4), S3-S8.
35. Pao W and Chmielecki J (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10, 760-774.
36. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, et al. (2006). Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 107, 2643-2652.
37. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546.
38. + T-cell clone following retroviral transduction with the IL-15 gene. Blood 109, 5168-5177.
39. Nagaraj S, Ziske C, and Schmidt-Wolf IG (2004). Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther 2, 12.
40. Markley JC and Sadelain M (2010). IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508-3519.
41. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, and Morgan RA (2005). Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 175, 7226-7234.
42. Budagian V, Bulanova E, Paus R, and Bulfone-Paus S (2006). IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17, 259-280.
43. + T cells. J Exp Med 202, 907-912.
44. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26, 5233-5239.
45. Alvarez-Vallina L and Hawkins RE (1996). Antigen-specific targeting of CD28-- mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26, 2304-2309.
46. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, and Sadelain M (1999). Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123-127.
47. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, and Rosenberg SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843-851.
48. Buning H, Uckert W, Cichutek K, Hawkins RE, and Abken H (2010). Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther 21, 1039-1042.
49. June CH (2007). Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117, 1466-1476.